BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
Bets on China Data, Differentiation Strategy
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
You may also be interested in...
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.
Growing Pains: Charting The Rapid Rise Of Chinese IO
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.
Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.